Veraxa Biotech Holding AG
VRXA
Get informed when a big investor buys or sells
+ FollowMarket Cap$475.46M
Close$
Share Statistics
| Market cap | $475.46 Million |
|---|---|
| Enterprise Value | $475.42 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -43.92% |
|---|---|
| Return on Assets | 2.47% |
| Return on Invested Capital | 137.62% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -143.75 |
| Enterprise Value to Net Income | 70 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Voyager Acquisition Corp.
8 employees
CEO: Christoph Antz Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a ...